Fly News Breaks for February 26, 2020
Feb 26, 2020 | 08:05 EDT
Oppenheimer analyst Esther Rajavelu lowered her price target for Jazz Pharmaceuticals to $154 from $183 following Q4 results, primarily due to higher opex. Following a year of "solid" pipeline execution in 2019, the analyst expects 2020 momentum from both commercial execution and clinical/regulatory catalysts, and continues to view Jazz as an "attractive" investment opportunity, with JZP-258, JZP-458, and lubrinectedin updates as key near-term catalysts. Rajavelu has an Outperform rating on the shares.
News For JAZZ From the Last 2 Days
There are no results for your query JAZZ